SELLAS Life Sciences
34 hedge funds and large institutions have $4.57M invested in SELLAS Life Sciences in 2017 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 6 increasing their positions, 11 reducing their positions, and 23 closing their positions.
1,396% more call options, than puts
Call options by funds: $1.26M | Put options by funds: $84K
0% less ownership
Funds ownership: 0.02% → 0.01% (-0%)
9% less capital invested
Capital invested by funds: $5.02M → $4.57M (-$453K)
32% less funds holding
Funds holding: 50 → 34 (-16)
45% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 11
70% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$360K |
| 2 |
VKH
Virtu KCG Holdings
New York
|
+$113K |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
+$104K |
| 4 |
ECM
Element Capital Management
New York
|
+$93.1K |
| 5 |
PP
Paloma Partners
Greenwich,
Connecticut
|
+$70.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$318K |
| 2 |
Millennium Management
New York
|
-$114K |
| 3 |
State Street
Boston,
Massachusetts
|
-$84.4K |
| 4 |
SG Americas Securities
New York
|
-$77K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$53.1K |
SLS Hedge Fund Activity: Q2 2017 in Review
34 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in SELLAS Life Sciences (SLS) for Q2 2017, worth a combined $4.57M — down 9% from $5.02M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of SLS and 7 opened new positions — a net loss of 16 holders — while 11 trimmed existing stakes and 6 added.
The largest buyer was Renaissance Technologies, adding an estimated $360K. The largest seller was BlackRock, cutting an estimated $318K.
- 34 institutional investors held SELLAS Life Sciences (SLS) as of Q2 2017, down from 50 in Q1 2017.
- Funds reported $4.57M of SELLAS Life Sciences stock for Q2 2017, down 9% quarter-over-quarter.
- 7 funds opened new SELLAS Life Sciences positions in Q2 2017 and 23 closed out, a net change of -16 holders.
- The largest SELLAS Life Sciences buyer in Q2 2017 was Renaissance Technologies, an estimated $360K added.
- The largest SELLAS Life Sciences seller in Q2 2017 was BlackRock, an estimated $318K sold.
Based on aggregated 13F filings for Q2 2017.